Suven, with Cohance and more, wants to become a CDMO powerhouse: Annaswamy Vaidheesh, executive chairman
Suven-Cohance Lifesciences merger announced to create 1st listed PE-led contract manufacturer in Indian pharma
Suven Pharmaceuticals Ltd on Friday (February 23) said the US Food & Drug Administration (US FDA) has completed the pre-approval inspections (PAI) and good manufacturing practices (GMP) inspections at the company's facilities in Hyderabad.
Private equity firm Advent International on Friday announced the completion of its majority acquisition of Hyderabad-based listed contract development and manufacturing organisation (CDMO) Suven Pharma. nnnRead more at: nhttps://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/pe-advent-completes-acquisition-of-suven-pharma-appoints-new-board-and-management-team/articleshow/104050279.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
Cabinet clears Advent's acquisition of Suven Pharma for Rs 9,589 crore
The acquisition is “by way of a share purchase agreement of December 26, 2022 and pursuant to the mandatory open offer in compliance with the Securities and Exchange Board of India (SEBI) (Substantial Acquisition of Shares and Takeovers) Regulations, 2011”, the competition regulator said in a statement.
Advent International (Advent), one of the largest and most experienced global private equity investors, has entered into a definitive agreement to acquire significant stake in Suven Pharmaceuticals (Suven Pharma) from the Jasti family, subject to regulatory approvals and conditions.
Private equity investors Blackstone and Advent International are in separate talks to buy a controlling stake in Suven Pharmaceuticals, Livemint reported on November 4, citing people with knowledge of the development.
The US Food and Drug Administration (USFDA) completed a pre-approval inspection at Casper Pharma formulations manufacturing facility situated at GMR Hyderabad SEZ.
Suven Pharm's Generic Glycopyrrolate Receives Approval in the U.S.